Dr Tanja De Gruijl | Professor of Translational Tumor Immunology
Vumc Cancer Center

Dr Tanja De Gruijl, Professor of Translational Tumor Immunology, Vumc Cancer Center

Tanja de Gruijl heads the Immunotherapy and Immune monitoring Lab at the Cancer Center of the VU University medical center (VUmc) in Amsterdam, where she has been appointed Professor of Translational Tumour Immunology. Her research ranges from preclinical topics to immune monitoring of Phase I-III clinical trials. Her main line of research is the in vivo targeting and modulation of dendritic cells (DC) in tumour-draining lymph nodes and  the tumour microenvironment. Further topics of research include tumour-mediated immune suppression, control of myeloid differentiation, and the targeting of NK, iNKT, and γδ-T cells. Her research has been supported by fellowships and grants from the Netherlands Organization for Scientific Research (NWO) and the Royal Dutch Cancer Society (KWF), and she is a recipient of a competitive research award of the Prostate Cancer Foundation. She is a member of the Grant Review committee of the Melanoma Research Alliance, a member of the scientific council of the Dutch Cancer Society, has chaired the Dutch Tumour Immunology Working Party, and is currently co-chair of the International Advisory Committee of the Society for the Immunotherapy of Cancer (SITC).


Day 3 Oct 12th Immune Profiling @ 14:50

  Immunoprofiling of tumour-draining lymph nodes: new targets for early intervention

  • Immunoprofiling of lymph nodes draining various tumor types has uncovered different immune suppressive mechanisms at play  
  • Different combinations of locally applied TLR-ligands and/or immune checkpoint inhibitors should be considered for therapeutic conditioning of lymph nodes draining different tumor types.
  • Immune suppression of migratory and resident DC subsets in melanoma sentinel lymph nodes is differentially related to locoregional and distant metastasis.
  • Local immune modulation of melanoma-draining lymph nodes by CpG or anti-CTLA4 leads to systemic T cell immunity and protection against metastatic spread.

back to speakers